Recent Updates
Recently added Catalysts

IDEAYA Biosciences, Inc.

IDYAFDA catalysts, PDUFA dates & pipeline intelligence
$27.4
▼ -2.96 · -9.75%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IDYA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $26.6852W HIGH $42.68
Volume
2.04 M
Value Traded
56.07 M
Short % Float
9.12%
Days to Cover
8.9
-16.25%Week
-18.96%1 Month
-29.51%3 Month
-7.59%6 Month
+43%5 Year
+107.86%All Time

Cash Data

Unlock IDYA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.65 B
EPS (TTM)
-4.34
P/E Ratio
-
Ent. Value
1.50 B
Total Shares
96.69 M
Float Shares
90.27 M
Insiders
6.64%
Institutions
103.40%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1/2 data readout
IDE849 (DLL3 TOP1 ADC)
small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC)
Phase 1/2Antibody-Drug Conjugates (ADCs)Oncology
Unlock every IDYA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IDYA Catalyst Timeline

Dated clinical, regulatory and corporate events for IDEAYA Biosciences, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for IDEAYA Biosciences, Inc.

442Total events
31Upcoming
86Tier-1 (high impact)
2018 to 2030Coverage

Upcoming catalysts 2

T2R&D Day
Subscribe to view catalyst details
T1Topline Readout
Subscribe to view catalyst details
IDE849

Event history 50

▲Type C MeetingIDE849FDA Meeting
Second US FDA Type C meeting on IDE849 registrational design in post-Imdelltra ES-SCLC
extensive-stage small cell lung cancer (ES-SCLC)source ↗
●Development Candidate NominationIDE101Preclinical
IDEAYA nominates IDE101, a first-in-class dual CDK inhibitor targeting CDKN2A-deficiency
CDKN2A-deficient solid tumorssource ↗
●Quarterly UpdateCorporate
Third Quarter 2026 financial results reported
◆Poster PresentationIDE849Presentation
Poster 3815P presentation of SHR-4849 (IDE849) long-term Phase 1 results at ESMO 2026
relapsed small cell lung carcinoma and other neuroendocrine carcinomassource ↗
▲Full ResultsIDE849Clinical Data
Updated Phase 1 results of IDE849 in relapsed SCLC and NEC presented at ESMO 2026
relapsed small cell lung cancer and other neuroendocrine carcinomassource ↗
▲Oral PresentationIDE849Presentation
Updated Phase 1 IDE849 data presented at ESMO 2026 (ORR 52.6% in NEC)
neuroendocrine carcinomas (NEC)source ↗
▲First Patient DosedIDE574Trial
First patient dosed with IDE574 plus fulvestrant
estrogen receptor positive metastatic breast cancersource ↗
●Management ChangeCorporate
Dr. Michael White promoted from Chief Scientific Officer to President, Research and Development
▲First Patient DosedDarovasertibFiledTrial
First patient dosed in OptimUM-11 Phase 3 adjuvant uveal melanoma trial
primary uveal melanoma (adjuvant therapy)source ↗
●Trial InitiationDarovasertibFiledTrial
OptimUM-11 global Phase 3 registrational trial of darovasertib + crizotinib initiated
primary uveal melanoma (adjuvant therapy)source ↗
Unlock the full IDYA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IDYA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-16IDE892 Phase 1 data presentation Phase 1
Unlock 14 more IDYA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Top 11%
Small Cap
(rank 81 of 725)
Percentile Rank
Showing 8 of 8 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
IDE892 Small MoleculesNCT07277413NSCLC AdenocarcinomaPhase 1 RECRUITING 260Apr 30, 2028
IDE-161 Small MoleculesNCT05787587Advanced or Metastatic Solid TumorsPhase 1 ACTIVE NOT_RECRUITING 216May 1, 2027
IDE849 Antibody-Drug Conjugates (ADCs)NCT07174583Small-cell Lung CancerPhase 1/2 RECRUITING 262Jul 1, 2029
IDE034 Small MoleculesNCT07503808Esophageal Squamous Cell CarcinomaPhase 1 RECRUITING 150Jul 30, 2027
IDE397 Small MoleculesNCT04794699Solid TumorPhase 1 ACTIVE NOT_RECRUITING 169Feb 4, 2027
IDE574 Small MoleculesNCT07540572CancerPhase 1 RECRUITING 155Jan 31, 2030
Darovasertib Small MoleculesNCT05907954Uveal MelanomaPhase 3 ACTIVE NOT_RECRUITING 1,130Apr 30, 2030
Darovasertib Small MoleculesNCT05987332Metastatic Uveal MelanomaPhase 2/3 ACTIVE NOT_RECRUITING 756Jan 15, 2028
Unlock the IDYA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IDYA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IDE849 relapsed small cell lung cancer and neuroendocrine carcinomasPhase 12026-10-23median os 2L SCLC: 17.4 months; overall response rate 2L SCLC: 72.5%; median os 2L plus 3L SCLC: 14.7 months; overall response rate 2L plus 3L SCLC: 68.3%; overall response rate SCLC with brain metastases: 76.9%; overall response rate NEC: 52.6%; median pfs 2L SCLC: 6.9 months; median pfs 2L plus 3L SCLC: 6.8 months; median pfs NEC: 7.0 months; nine month os rate NEC: 82.4%Read MoreIDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine CarcinomasRead More
Scroll for more · summaries link to the source press release
Unlock every IDYA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IDYA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Hata Yujiro SDirector, Officer (President and CEO)Option 26,338 717,033 held$4.31 10/06/2026
Unlock the full IDYA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
BAKER BROS. ADVISORS 0.9 % 192.49 M 5.01 M
Unlock every fund holding IDYA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IDYA
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IDYA ownership
Insider and institutional ownership, quarter by quarter.

IDYA Short Interest

Shares sold short, counted twice a month.

9.12%
Short % of Float
of tradable shares sold short
8.2M
Shares Sold Short
-9.3% vs prior count
8.9 High
Days to Cover
trading days of normal volume to buy every short share back
928.5K
Avg Daily Volume
the average used for days to cover
Unlock IDYA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock IDYA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IDYA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IDYA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IDYA ranks across every disease it competes in

Competitive Position is a premium feature
See how IDYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IDYA News

IDYA
Nov 16, 2026
IDYAFDA Updates
▼ -9.7%on this news

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

IDEAYA Biosciences announced a successful Type C meeting with the FDA regarding IDE849, a DLL3-targeting ADC for neuroendocrine carcinomas. The company plans to initiate a single-arm extension cohort and a randomized Phase 3 trial to support potential accelerated and full approval. IDE849 has shown promising efficacy with a 52.6% overall response rate in previous trials.

Read more →
IDYA
Nov 15, 2026
IDYAPhases
▼ -9.7%today

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

IDEAYA Biosciences has nominated IDE101 as a development candidate targeting CDKN2A-deficiency in solid tumors. The drug shows encouraging preclinical activity, particularly in pancreatic cancer. IND-enabling studies are currently underway, with plans to file for FDA approval in the first half of 2027. The company aims to combine IDE101 with other therapies to enhance efficacy.

Read more →
IDYA
Nov 4, 2026
IDYAConferences/Events

IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

IDEAYA Biosciences will participate in key investor events on November 16-17, 2026, in London. The events will feature discussions on IDE892, a potential best-in-class PRMT5 inhibitor, and updates on RAS-driven cancer therapies. Registration is required for both in-person and virtual attendance.

Read more →
IDYA
Nov 3, 2026
IDYAGeneral

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

IDEAYA Biosciences reported strong financial results for Q3 2026, including a successful NDA submission for darovasertib in metastatic uveal melanoma. The company presented promising data at ESMO 2026, highlighting the drug's potential as a foundational therapy. However, IDEAYA also announced the closure of the Phase 3 OptimUM-010 trial due to enrollment issues, resulting in cost reallocations.

Read more →
IDYA
Oct 30, 2026
IDYAGeneral

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences announced the grant of non-qualified stock options for 99,600 shares to four new employees as part of its 2023 Inducement Plan. The options, priced at $32.89 per share, will vest over four years, promoting long-term commitment. This action complies with Nasdaq Listing Rule 5635(c)(4).

Read more →
IDYA
Oct 23, 2026
IDYAPhases

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

IDEAYA Biosciences announced updated Phase 1 results for IDE849, showing promising anti-tumor activity in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs). The study reported a median overall survival of 17.4 months in second-line SCLC and a 72.5% overall response rate. Plans for two Phase 3 trials are underway following successful FDA meetings.

Read more →
IDYA
Oct 19, 2026
IDYAPhases

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IDEAYA Biosciences presented encouraging data on darovasertib at ESMO 2026, highlighting its effectiveness in treating metastatic and primary uveal melanoma. The trials OptimUM-01 and OptimUM-02 demonstrated significant clinical benefits, including improved progression-free survival and overall survival rates. Additionally, the OptimUM-09 trial showed promising tumor shrinkage and eye preservation rates, supporting darovasertib's potential as a foundational therapy.

Read more →
IDYA
Sep 28, 2026
IDYAGeneral

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

IDEAYA Biosciences has promoted Dr. Michael White to President of Research and Development, effective September 28, 2026. Dr. White, previously Chief Scientific Officer, has been instrumental in advancing the company's oncology pipeline. His leadership is expected to enhance IDEAYA's efforts in developing targeted therapies for various cancers, aiming to address significant unmet medical needs.

Read more →
IDYA
Sep 9, 2026
IDYAPhases

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

IDEAYA Biosciences and Servier have announced the dosing of the first patient in the OptimUM-11 Phase 3 trial. This study evaluates the combination of darovasertib and crizotinib as an adjuvant therapy for patients with primary uveal melanoma at risk of metastasis. The trial aims to establish a new treatment option in a setting with significant unmet needs.

Read more →
IDYA
Sep 1, 2026
IDYAConferences/Events

IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

IDEAYA Biosciences has announced its upcoming Investor R&D Day in London on November 16, 2026, where it will discuss its development strategies for pancreatic cancer. The company will also participate in several investor conferences in September 2026, featuring key management discussions. A live audio webcast will be available for those unable to attend in person.

Read more →
IDYA
Aug 31, 2026
IDYAFDA Updates

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

IDEAYA Biosciences announced a successful FDA Type C meeting regarding the Phase 3 registrational trial design for IDE849, a DLL3-targeting ADC in extensive stage small cell lung cancer (ES-SCLC). The company aims to begin the trial by the end of 2026, with a focus on overall response rate and median overall survival as primary endpoints. The study will enroll approximately 400 patients and evaluate various dose levels.

Read more →
IDYA
Aug 19, 2026
IDYAPhases

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

IDEAYA Biosciences has announced a clinical collaboration with Genentech to evaluate IDE892, a potential best-in-class PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor RG6620. This study targets patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma. Genentech will sponsor the trial, and both companies will retain commercial rights to their respective compounds.

Read more →
IDYA
Aug 4, 2026
IDYAFDA Updates

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences reported positive results from its OptimUM-02 trial for darovasertib in metastatic uveal melanoma, with plans for a new drug application filing. The company also announced upcoming data presentations at ESMO and a clinical collaboration with Roche for IDE892 in pancreatic cancer. Despite a strong cash position of $1.24 billion, the company reported an increased net loss for the quarter.

Read more →
IDYA
Jul 27, 2026
IDYAPhases

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences has initiated the Part 2 monotherapy expansion of IDE892 in its Phase 1/2 trial for MTAP-deleted pancreatic and lung cancers. The drug exhibits a promising profile with selective binding properties and has achieved target exposures. The ongoing dose escalation has not yet reached the maximum tolerated dose, indicating further potential for efficacy.

Read more →
IDYA
Jul 17, 2026
IDYAConferences/Events

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

IDEAYA Biosciences announced three abstract presentations at the 2026 ESMO meeting, highlighting updates from its clinical pipeline. The presentations will cover ongoing trials of darovasertib in uveal melanoma and IDE849 in small cell lung carcinoma. The company aims to demonstrate the potential of these therapies as new treatment options.

Read more →
IDYA
Jun 17, 2026
IDYAGeneral

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences has elected Yujiro S. Hata as Chairman of the Board. Hata, who is also the President and CEO, has been instrumental in the company's evolution into a leading precision medicine oncology firm. The company is focused on developing breakthrough therapies for cancer, addressing significant unmet medical needs.

Read more →

About IDEAYA Biosciences, Inc.

South San Francisco, CA 145 employees ideayabio.com
Headquarters5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE
Trade the next IDYA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime